D. Diekema

Infectious Diseases · 2001–2019

A researcher in the Science corpus: 7 papers; trusts 9 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

• Infectious Diseases — 77 citations into it; #198 of 589 by trust here, #162 by citations
• Epidemiology — 68 citations into it; #866 of 2,148 by trust here, #840 by citations
• Applied Microbiology and Biotechnology — 13 citations into it
• Small Animals — 11 citations into it; #457 of 462 by trust here, #377 by citations
• Cell Biology — 10 citations into it
• Clinical Biochemistry — 6 citations into it

Whom D. Diekema trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. M. Pfaller
2. C. León
3. D. Trofa
4. M. Morrell
5. Georgios Chamilos

Who trusts D. Diekema overall

1. M. Pfaller
2. J. Guinea
3. Aaron Tande
4. F. Lowy
5. L. Piddock
6. François L. Mayer

Papers from D. Diekema's perspective

Ordered by how strongly the researchers D. Diekema trusts endorse each paper. Same corpus, a different order for every researcher.

1. Attributable mortality of nosocomial candidemia, revisited. (Clinical Infectious Diseases)
2. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. (Clinical Infectious Diseases)
3. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. (Clinical Infectious Diseases)
4. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (Clinical Microbiology Reviews)
5. Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality (Antimicrobial Agents and Chemotherapy)
6. Comparison of caspofungin and amphotericin B for invasive candidiasis. (New England Journal of Medicine)
7. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. (Clinical Infectious Diseases)
8. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. (New England Journal of Medicine)
9. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. (Clinical Infectious Diseases)
10. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (Clinical Infectious Diseases)

Their papers

• Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016 (2019) — 718 citations
• Epidemiology of Invasive Mycoses in North America (2010) — 929 citations
• Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion (2010) — 759 citations
• Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) — 4,086 citations
• Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus (2004) — 735 citations
• Attributable mortality of nosocomial candidemia, revisited. (2003) — 1,182 citations
• Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. (2001) — 1,504 citations